Oncogenic B-Myb Is Associated With Deregulation of the DREAM-Mediated Cell Cycle Gene Expression Program in High Grade Serous Ovarian Carcinoma Clinical Tumor Samples
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oncogenic B-Myb Is Associated With Deregulation of the DREAM-Mediated Cell Cycle Gene Expression Program in High Grade Serous Ovarian Carcinoma Clinical Tumor Samples
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-04
DOI
10.3389/fonc.2021.637193
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)
- (2019) Ryusuke Murakami et al. GYNECOLOGIC ONCOLOGY
- E2F1 as a molecular drug target in ovarian cancer
- (2019) Rossella Farra et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- RB, p130 and p107 differentially repress G1/S and G2/M genes after p53 activation
- (2019) Amy E Schade et al. NUCLEIC ACIDS RESEARCH
- Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition
- (2018) Pingping Fang et al. MOLECULAR CANCER RESEARCH
- Identification of Drivers of Aneuploidy in Breast Tumors
- (2018) Katherine Pfister et al. Cell Reports
- MuvB: A Key to Cell Cycle Control in Ovarian Cancer
- (2018) Audra N. Iness et al. Frontiers in Oncology
- PCNA-associated factor P15PAF , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients
- (2018) Chengjuan Jin et al. INTERNATIONAL JOURNAL OF CANCER
- The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb
- (2018) Audra N. Iness et al. ONCOGENE
- Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer
- (2017) Gina L. Westhoff et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis
- (2017) Julian Musa et al. Cell Death & Disease
- Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy
- (2017) Patrick Wolter et al. Oncotarget
- Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes
- (2016) Ryusuke Murakami et al. AMERICAN JOURNAL OF PATHOLOGY
- A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in Cancer Cell Dormancy
- (2016) James MacDonald et al. MOLECULAR CANCER RESEARCH
- Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks
- (2016) Martin Fischer et al. NUCLEIC ACIDS RESEARCH
- An important role for Myb-MuvB and its target gene KIF23 in a mouse model of lung adenocarcinoma
- (2016) F Iltzsche et al. ONCOGENE
- Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression
- (2015) Carter J Barger et al. Oncotarget
- FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance
- (2014) Stefania Zona et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Cyclin B2 and p53 control proper timing of centrosome separation
- (2014) Hyun-Ja Nam et al. NATURE CELL BIOLOGY
- A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer
- (2013) Zsuzsanna Mihály et al. BREAST CANCER RESEARCH AND TREATMENT
- Effects ofTP53mutational status on gene expression patterns across 10 human cancer types
- (2013) Neha Parikh et al. JOURNAL OF PATHOLOGY
- A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
- (2013) L. J. Solin et al. JNCI-Journal of the National Cancer Institute
- curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome
- (2013) Benjamin Frederick Ganzfried et al. Database-The Journal of Biological Databases and Curation
- The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression
- (2012) S. Sadasivam et al. GENES & DEVELOPMENT
- The Forkhead Transcription Factor FOXM1 Controls Cell Cycle-Dependent Gene Expression through an Atypical Chromatin Binding Mechanism
- (2012) X. Chen et al. MOLECULAR AND CELLULAR BIOLOGY
- Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-Damage
- (2012) Marianna Halasi et al. PLoS One
- DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly
- (2011) L. Litovchick et al. GENES & DEVELOPMENT
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
- (2010) Robert J. Kurman et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
- (2010) C. J. Allegra et al. JNCI-Journal of the National Cancer Institute
- Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction
- (2009) Yan-Li Li et al. ANALYTICAL BIOCHEMISTRY
- A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2
- (2009) Samuel C. Mok et al. CANCER CELL
- B-MYB Is Required for Recovery from the DNA Damage-Induced G2 Checkpoint in p53 Mutant Cells
- (2009) M. Mannefeld et al. CANCER RESEARCH
- A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
- (2008) T. Bonome et al. CANCER RESEARCH
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
- (2008) R. W. Tothill et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation